Pharmacokinetic Considerations to Optimize Clinical Outcomes for COVID-19 Drugs

Overview

Journal Trends Pharmacol Sci

Specialty Pharmacology

Date 2022 Nov 14

PMID 36374805

Authors

Chukwunonso K Nwabufo

Reina Bendayan

Affiliations

Soon will be listed here.

Abstract

The development of clinically effective drugs that could complement existing vaccines is urgently needed to reduce the morbidity and mortality associated with COVID-19. Drug-metabolizing enzymes, membrane-associated drug transporters, and inflammatory responses can partly determine the safety and efficacy of COVID-19 drugs by controlling their concentrations in both the systemic circulation and in peripheral tissues. It is still unknown how these factors affect how well COVID-19 drugs work in the clinic. We explore how drug metabolism and transport, as well as SARS-CoV-2-associated inflammatory response at disease target sites, may affect the clinical outcomes of COVID-19 drugs. In addition, we provide expert opinion on potential strategies for overcoming the clinical pharmacology and pathophysiological obstacles to improve COVID-19 drug effectiveness.

Citing Articles

Obesity and its Relationship with Covid-19: A Review of the Main Pharmaceutical Aspects.

Hodel K, Fonseca A, Barbosa I, Medina C, Alves B, Maciel C Curr Pharm Biotechnol. 2024; 25(13):1651-1663.

PMID: 38258769 DOI: 10.2174/0113892010264503231108070917.

Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations.

Nwabufo C Cancer Chemother Pharmacol. 2023; 93(2):89-105.

PMID: 37594572 DOI: 10.1007/s00280-023-04575-y.

Metabolism Pathways of Major Therapeutics for Treating Monkeypox Mono- and Co-infection with Human Immunodeficient Virus or SARS-CoV-2.

Yan D, Yan B Curr Drug Metab. 2023; 24(4):240-249.

PMID: 37287302 PMC: 11089469. DOI: 10.2174/1389200224666230607124102.

SARS-CoV-2 infection dysregulates the expression of clinically relevant drug metabolizing enzymes in Vero E6 cells and membrane transporters in human lung tissues.

Nwabufo C, Hoque M, Yip L, Khara M, Mubareka S, Pollanen M Front Pharmacol. 2023; 14:1124693.

PMID: 37180730 PMC: 10172598. DOI: 10.3389/fphar.2023.1124693.

References

Spinner C, Gottlieb R, Criner G, Lopez J, Cattelan A, Soriano Viladomiu A . Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(11):1048-1057. PMC: 7442954. DOI: 10.1001/jama.2020.16349. View

Garcia-Beltran W, Lam E, St Denis K, Nitido A, Garcia Z, Hauser B . Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021; 184(9):2372-2383.e9. PMC: 7953441. DOI: 10.1016/j.cell.2021.03.013. View

Deb S, Reeves A, Hopefl R, Bejusca R . ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential. Pharmaceuticals (Basel). 2021; 14(7). PMC: 8308800. DOI: 10.3390/ph14070655. View

Nwabufo C, Aigbogun O, Allen K, Owens M, Lee J, Phenix C . Employing metabolism to guide design of F-labelled PET probes of novel α-synuclein binding bifunctional compounds. Xenobiotica. 2021; 51(8):885-900. DOI: 10.1080/00498254.2021.1943566. View

Ziegler C, Allon S, Nyquist S, Mbano I, Miao V, Tzouanas C . SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell. 2020; 181(5):1016-1035.e19. PMC: 7252096. DOI: 10.1016/j.cell.2020.04.035. View

Ventura-Lopez C, Cervantes-Luevano K, Aguirre-Sanchez J, Flores-Caballero J, Alvarez-Delgado C, Bernaldez-Sarabia J . Treatment with metformin glycinate reduces SARS-CoV-2 viral load: An in vitro model and randomized, double-blind, Phase IIb clinical trial. Biomed Pharmacother. 2022; 152:113223. PMC: 9159967. DOI: 10.1016/j.biopha.2022.113223. View

Nwabufo C, Aigbogun O . Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson's disease. J Neurol. 2022; 269(11):5762-5786. PMC: 9281355. DOI: 10.1007/s00415-022-11267-9. View

Aziz M, Fatima R, Assaly R . Elevated interleukin-6 and severe COVID-19: A meta-analysis. J Med Virol. 2020; 92(11):2283-2285. PMC: 7267383. DOI: 10.1002/jmv.25948. View

Su F, Patel G, Hu S, Chen W . Induction of mucosal immunity through systemic immunization: Phantom or reality?. Hum Vaccin Immunother. 2016; 12(4):1070-9. PMC: 4962944. DOI: 10.1080/21645515.2015.1114195. View

10.

Kuban W, Daniel W . Cytochrome P450 expression and regulation in the brain. Drug Metab Rev. 2020; 53(1):1-29. DOI: 10.1080/03602532.2020.1858856. View

11.

Ehrhardt C, Backman P, Couet W, Edwards C, Forbes B, Friden M . Current Progress Toward a Better Understanding of Drug Disposition Within the Lungs: Summary Proceedings of the First Workshop on Drug Transporters in the Lungs. J Pharm Sci. 2017; 106(9):2234-2244. DOI: 10.1016/j.xphs.2017.04.011. View

12.

Patocka J, Kuca K, Oleksak P, Nepovimova E, Valis M, Novotny M . Rapamycin: Drug Repurposing in SARS-CoV-2 Infection. Pharmaceuticals (Basel). 2021; 14(3). PMC: 8001969. DOI: 10.3390/ph14030217. View

13.

Enlo-Scott Z, Backstrom E, Mudway I, Forbes B . Drug metabolism in the lungs: opportunities for optimising inhaled medicines. Expert Opin Drug Metab Toxicol. 2021; 17(5):611-625. DOI: 10.1080/17425255.2021.1908262. View

14.

Berg T, Hegelund-Myrback T, Ockinger J, Zhou X, Brannstrom M, Hagemann-Jensen M . Expression of MATE1, P-gp, OCTN1 and OCTN2, in epithelial and immune cells in the lung of COPD and healthy individuals. Respir Res. 2018; 19(1):68. PMC: 5910606. DOI: 10.1186/s12931-018-0760-9. View

15.

Miller S, Cherrington N . Transepithelial transport across the blood-testis barrier. Reproduction. 2018; 156(6):R187-R194. PMC: 6437009. DOI: 10.1530/REP-18-0338. View

16.

Hamm G, Backstrom E, Brulls M, Nilsson A, Strittmatter N, Andren P . Revealing the Regional Localization and Differential Lung Retention of Inhaled Compounds by Mass Spectrometry Imaging. J Aerosol Med Pulm Drug Deliv. 2019; 33(1):43-53. DOI: 10.1089/jamp.2019.1536. View

17.

Hoffmann M, Arora P, Gross R, Seidel A, Hornich B, Hahn A . SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021; 184(9):2384-2393.e12. PMC: 7980144. DOI: 10.1016/j.cell.2021.03.036. View

18.

Nwabufo C . Relevance of ABC Transporters in Drug Development. Curr Drug Metab. 2022; 23(6):434-446. DOI: 10.2174/1389200223666220621113524. View

19.

Pilla Reddy V, El-Khateeb E, Jo H, Giovino N, Lythgoe E, Sharma S . Pharmacokinetics under the COVID-19 storm. Br J Clin Pharmacol. 2020; 89(1):158-186. PMC: 7753415. DOI: 10.1111/bcp.14668. View

20.

Ambrus C, Bakos E, Sarkadi B, Ozvegy-Laczka C, Telbisz A . Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics. Sci Rep. 2021; 11(1):17810. PMC: 8426393. DOI: 10.1038/s41598-021-97160-3. View